NRG Oncology's GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)

被引：4
|
作者：
Zumsteg, Z. [1 ]
Karrison, T. [2 ]
Michaelson, M. D. [3 ]
Tran, P. [4 ]
Kudchadker, R. [5 ]
Feng, F. [6 ]
机构：
[1] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA
[2] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA
[3] Harvard Med Sch, Dept Med Oncol, Massachusetts Gen Hosp, Boston, MA 02115 USA
[4] Johns Hopkins, Dept Radiat Oncol, Baltimore, MD USA
[5] MD Anderson, Dept Radiat Oncol, Houston, TX USA
[6] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
689TiP
引用
收藏
页码：S546 / S546
页数：1
相关论文
共 50 条
  • [21] NEOADJUVANT ENZALUTAMIDE AND ANDROGEN DEPRIVATION IN HIGH-RISK PROSTATE CANCER: INITIAL IMAGING AND SURGICAL FINDINGS FROM A PHASE II CLINICAL TRIAL
    Gold, Samuel
    Marhamati, Sahwn
    Harmon, Stephanie
    Bloom, Jonathan
    Karzai, Fatima
    Hale, Graham
    Rayn, Kareem
    Sabarwal, Vik
    Mehralivand, Sherif
    Czarniecki, Marcin
    Smith, Clayton
    VanderWeele, David
    Dahut, William
    Turkbey, Baris
    Pinto, Peter
    JOURNAL OF UROLOGY, 2018, 199 (04): : E306 - E306
  • [22] Phase I/II study of sorafenib concurrent with androgen deprivation and radiotherapy in treatment of intermediate- and high-risk localized prostate cancer
    Talwar, S.
    Cohen, S. M.
    Romas, N. A.
    Ennis, R. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Randomized Phase 3 Trial of Adjuvant Androgen Deprivation in Combination With High-Dose Conformal Radiation Therapy in Intermediate- and High-Risk Localized Prostate Cancer
    Zapatero, A.
    Guerrero, A.
    Maldonado, J.
    Alvarez, A.
    Gonzalez San Segundo, C.
    Cabeza Rodriguez, M.
    Macias, V.
    Pedro-Olive, A.
    Casas, F.
    Boladeras, A.
    Martin de Vidales, C.
    Vazquez de la Torre, M.
    Calvo, F. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S1 - S1
  • [24] A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902
    Rosenthal, Seth A.
    Hunt, Daniel
    Sartor, Oliver
    Pienta, Kenneth J.
    Gomella, Leonard
    Grignon, David
    Rajan, Raghu
    Kerlin, Kevin J.
    Jones, Christopher U.
    Dobelbower, Michael
    Shipley, William U.
    Zeitzer, Kenneth
    Hamstra, Daniel A.
    Donavanik, Viroon
    Rotman, Marvin
    Hartford, Alan C.
    Michalski, Jeffrey
    Seider, Michael
    Kim, Harold
    Kuban, Deborah A.
    Moughan, Jennifer
    Sandler, Howard
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (02): : 294 - 302
  • [25] RTOG/NRG 1115 Quality of Life of Phase III Dose Escalated Radiation Therapy (RT) and Standard Androgen Deprivation Therapy (ADT) with GnRH Agonist vs. Dose Escalated RT and ADT with GnRH Agonist and Orteronel (TAK-700) for Men with High-Risk Prostate
    Bruner, D. W.
    Pugh, S.
    Michaelson, D.
    Hamstra, D. A.
    Bachand, F.
    Master, V.
    Torres, M.
    Kaplan, I. D.
    Rosenthal, S. A.
    Roach, M., III
    Raben, A.
    Michalski, J. M.
    Kavadi, V. S.
    Ferguson, M.
    Morgan, S. C.
    D'Souza, D. P.
    DeMora, L.
    Sandler, H. M.
    Movsas, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E214 - E214
  • [26] Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer
    Lin, Jianqing
    Den, Robert B.
    Greenspan, Jacob
    Showalter, Timothy N.
    Hoffman-Censits, Jean H.
    Lallas, Costas D.
    Trabulsi, Edouard J.
    Gomella, Leonard G.
    Hurwitz, Mark D.
    Leiby, Benjamin
    Dicker, Adam P.
    Kelly, W. Kevin
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 939 - 947
  • [27] Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial
    Dai, Bo
    Zhang, Sheng
    Wan, Fang-Ning
    Wang, Hong-Kai
    Zhang, Jun -Yu
    Wang, Qi-Feng
    Kong, Yun-Yi
    Ma, Xue-Jun
    Mo, Miao
    Zhu, Yao
    Qin, Xiao-Jian
    Lin, Guo-Wen
    Ye, Ding -Wei
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (05): : 519 - 525
  • [28] Neoadjuvant IMC-A12 and combined androgen deprivation with prostatectomy for high-risk prostate cancer: A phase II trial
    Dean, J. P.
    Plymate, S. R.
    Dalkin, B. L.
    Ellis, W. J.
    Lin, D. W.
    Wright, J. L.
    Corman, J. M.
    True, L. D.
    Lange, P. H.
    Montgomery, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial.
    Nabid, Abdenour
    Garant, Marie-Pierre
    Martin, Andre-Guy
    Bahary, Jean-Paul
    Lemaire, Celine
    Vass, Sylvie
    Bahoric, Boris
    Archambault, Robert
    Vincent, Francois
    Bettahar, Redouane
    Carrier, Nathalie
    Duclos, Marie
    Souhami, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
    Sartor, Oliver
    Karrison, Theodore G.
    Sandler, Howard M.
    Gomella, Leonard G.
    Amin, Mahul B.
    Purdy, James
    Michalski, Jeff M.
    Garzotto, Mark G.
    Pervez, Nadeem
    Balogh, Alexander G.
    Rodrigues, George B.
    Souhami, Luis
    Reaume, M. Neil
    Williams, Scott G.
    Hannan, Raquibul
    Jones, Christopher U.
    Horwitz, Eric M.
    Rodgers, Joseph P.
    Feng, Felix Y.
    Rosenthal, Seth A.
    EUROPEAN UROLOGY, 2023, 84 (02) : 156 - 163
12345